Unfortunately, we found that those reported small molecule inhibitors of atypical PKC (ATM, ANF and Oncrasin) were either not selective to PRKCI-amplified ovarian cancer cells or cytotoxic to non-cancerous FTSE cells at effective doses. This evidence concerns the gene PRKCI and ovarian carcinoma.